摘要
目的比较单用TD方案（沙利度胺＋地塞米松，对照组）与TD联合米托蒽醌方案（治疗组）治疗多发性骨髓瘤（MM）的临床疗效和不良反应。方法治疗组23例，沙利度胺开始剂量为100 mg/d，每2 d增加50-100 mg，直到200 mg/d。米托蒽醌2 mg/d，地塞米松20-40 mg/d静脉滴注，第1-4天，28 d为1疗程。对照组，23例，沙利度胺、地塞米松的剂量和用法同治疗组。结果治疗组总有效率为78.2%（18/23），对照组总有效率为65.2%（15/23），两组间差异无统计学意义，（P〉0.05）。治疗组中位显效时间（time to response，TTR）为36.6 d（30-60）d。对照组的中位TTR为50 d（30-90）d。（P〈0.05）。治疗组不良反应与对照组差异无统计学意义。结论米托蒽醌联合沙利度胺、地塞米松方案治疗MM较单用TD方案中位显效时间短，起效快，肿瘤负荷下降快，患者耐受性好。
Objective To compare the efficacy and toxicity of TD treatment （Thalidomide ＋ Dexamethasone, as control group） and TD plus Mitoxantrone treatment （treatment group） on patients with multiple myeloma （MM）. Methods Each of twenty-three patients in treatment group were initially administered Thalidomide at dose of 100 mg/d, then increased 50 mg/d every two days up till 200 mg/d. The regimen also consisted of 4 days of intravenous Dexamethasone （ 20 - 40 ） mg/d and Mitoxantrone 2 mg/d, each cycle lasted for 28 d. Mean while, the twenty-three cases in control group were received chemotherapy with TD regimen alone. Results The total response rate was 78.2% （ 18/23 ） and 65.2% （15/23） in treatment group and control group respectively, which demonstrated no significant difference （ P 〉 0.05）. The median time to response （TTR） in treatment group was 36.6 d （ 30 - 60） d. While the median TTR in control group was 50.0 d （ 30 - 90） d. （ P 〈 0.05 ）. The adverse effects had no significant differences between two groups. Conclusion The median TTR in Mitoxantrone plus TD regimen group is shorter than that in TD regimen group and the MTD therapy is well tolerated.
出处
《同济大学学报（医学版）》
CAS
2009年第3期92-95,共4页
Journal of Tongji University(Medical Science)
关键词
沙利度胺
米托蒽醌
多发性骨髓瘤
疗效
Thalidomide
Mitoxantrone
multiple myeloma
curative effect
